On December 28th, 2018, National Medical Products Administration (NMPA) issued ‘Administrative Regulations of Drug and Medical Device Overseas Inspection’ (NMPA order No. 101 2018) implemented from the date of publication. Overseas inspection is the global common way for medical device inspection and one of the important steps for Chinese medical device inspection to be internationalized. The Regulations have essential effects for supervising overseas enterprises to comply with Chinese regulations.
NMPA is responsible for medical device overseas inspection. NMPA makes inspection tasks through risk evaluation and random selection in accordance with the suggestions of draft inspecting medical devices, R&D site and manufacturing site from relevant departments. Center for Food and Drug Inspection of NMPA (CFDI) is responsible for specific organization and implementation of medical device overseas inspection. Relevant departments will assist with the overseas inspection.
Overseas MAH shall submit CFDI ‘Letter of Authorization’ and ‘Basic Information Table of Overseas Inspecting Products’ in 20 workdays and submit main documents of inspecting site and other necessary materials in 40 workdays after receiving ‘Announcement of Overseas Inspection’.
There are several new regulations that overseas enterprises need to consider:
-Overseas inspection doesn’t only contain manufacturing site but also includes overseas R&D location.
-Delay, obstruction, restriction, and rejection for the inspection are all determined as ‘Fail’.
-If the enterprise has serious quality risk, NMPA will immediately conduct risk control measures.
-CFDI can acquire and inspect relevant technical files with crypto-security and include them into inspection files.
-The enterprise should keep normal condition and cooperate to inspect relevant equipment and sites. In accordance with inspection schedule, the enterprise shall arrange dynamic manufacturing process of inspected products and provide needed documents, records, e-data in time.
-If necessary, CFDI can sample and seal products with sampling documents. MAH shall ensure the package and transportation condition of the sample cannot affect sample quality.
NMPA clarifies overseas inspection process and responsibilities of NMPA and overseas MAH through these new regulations. Under this stringent regulations, overseas MAH should review and inspect all process and documents about R&D and manufacturing. They also have to ensure quality of the products and running conditions of the equipment. On the other hand, overseas MAH can consider to apply for being a domestic MAH in China. Shanghai is the first city that allow individuals or independent institutes as medical device MAH to authorize other factories to manufacture medical devices. In this way, overseas MAH can register their medical devices as domestic products in China.
For English version of Administrative Regulations of Drug and Medical Device Overseas Inspection, please email info@ChinaMedDevice.com. We charge nominal fees for the translation.
Keep yourself updated with NMPA (CFDA) News Roundup, click HERE to opt-in. For market access newsletter, click HERE. For CRO services in China, click HERE.
About ChinaMed Device, LLC
ChinaMed Device, LLC (www.ChinaMedDevice.com), a Boston headquartered company, provides regulatory and commercialization turnkey solutions for western medical device, IVD, CDx and combination products to enter China. Our NMPA (CFDA) regulatory services include: RA, regulatory strategy, regulatory submissions, clinical evaluation reports (CER), clinical trials, QA, GMP and post-market compliance. Our commercialization services include: market assessment research, reimbursement, partnership strategies, and distribution qualification. We are a NMPA (CFDA) certified legal agent with offices in Boston and Beijing enabling us to service our clients 24/7.